비교리스트

 카트 문의
시장보고서
상품코드
1414926

면역관문억제제 시장 - 유형별, 용도별 : 세계 기회 분석 및 산업 예측(2023-2032년)

Immune Checkpoint Inhibitors Market By Type, By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 248 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

면역관문억제제(ICI) 시장은 2022년에는 401억 달러로 평가되었으며, 2023년부터 2032년까지 16.8%의 연평균 복합 성장률(CAGR)로 성장할 전망이며, 2032년에는 1,894억 달러에 이를 것으로 추정됩니다.

Immune Checkpoint Inhibitors Market-IMG1

암세포는 면역 체계의 검출과 파괴를 피하기 위해 이러한 관문을 악용합니다. 면역관문억제제는 PD-1(프로그램 세포 사단백질 1), PD-L1(프로그램 사멸 리간드 1), CTLA-4(세포독성 T 림프구 관련 단백질 4)와 같은 특정 단백질을 표적화합니다. 그리고 차단하여 작동합니다. 이러한 단백질을 억제함으로써, 이러한 약제는 면역계가 보다 효과적으로 암세포를 확인하고 싸우는 것을 가능하게 합니다.

면역관문억제제 시장의 성장을 가속하는 주요 요인은 연구개발의 진전, 암 환자 증가, 임상시험수 증가, 연구 이니셔티브의 확대, 전략적 제휴, 신규 적응증의 승인 확대 등입니다. 암은 여전히 세계 사망 원인 1위이며, 다양한 암종으로 진단되는 증례가 계속 증가하고 있습니다. 예를 들어 미국 국립암연구소 암제어 및 인구과학부(DCCPS)에 따르면 미국에서는 623,405명이 전이성 유방암, 전립선암, 폐암, 대장암 또는 전이성 흑색종을 앓고 있습니다. 암 부담이 증가함에 따라, 보다 효과적인 치료 옵션에 대한 긴급한 요구가 증가하고, 면역관문억제제에 대한 수요가 증가하고 있습니다.

게다가, 면역관문억제제에 초점을 맞춘 임상시험의 수가 증가하고 있는 것도 시장 성장을 뒷받침할 것으로 예상됩니다. 제약회사, 생명공학기업, 학술기관 간에는 임상연구에 자원을 나누는 경향이 강해지고 있습니다. 이 투자는 다양한 암종에서 면역관문억제제의 안전성, 효능 및 가용성을 조사하는 것을 목표로 합니다. 이러한 임상시험은 신규약제 조합의 검토, 치료반응의 평가, 예측 바이오마커의 식별에 중점을 두고 있으며, 면역주도형 치료의 이해를 넓히는 데 크게 기여하고 있습니다. 예를 들어, 2023년 7월, Merck&Co., Inc. 및 Moderna, Inc.는 절제된 고위험(단계 IIB-IV) 흑색종 환자에서 수술 후 보조 요법으로 시험 중 개별화된 새로운 항원 요법(INT)인 V940(mRNA-4157)을 Merck의 항-PD-1 요법인 KEYTRUDA와 병용하는 매우 중요한 3상 랜덤화 V940-001 임상시험의 개시를 발표했습니다. 이러한 임상시험의 결과는 약물개척의 원동력이 될 뿐만 아니라 치료방침의 결정에도 도움이 되므로 면역관문억제제 시장의 성장을 더욱 뒷받침합니다.

게다가 제약기업, 생명공학기업, 학술기관의 전략적 제휴는 면역관문억제제 시장의 성장을 가속하는 중요한 요인으로 부상하고 있습니다. 파트너십과 제휴는 전문 지식, 자원, 기술의 통합을 촉진하고 창약 개발 프로세스를 가속화합니다. 예를 들어, 2020년 5월, 세계의 바이오 의약품 기업인 Innovent Biologics, Inc.와 텍사스 대학 MD 앤더슨 암 센터는 이노벤트의 항PD-1 단클론항체인 TYVYT(신틸리맙 주사제)를 희소암 치료 약으로 미국에서 공동 개발하는 전략적 제휴 계약을 체결했다고 발표했습니다. 이러한 공동연구에 의해 몇개의 면역관문억제제 개발 및 상업화에 성공해, 암 영역에 있어서의 면역관문억제제의 응용 범위가 넓어지고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장 정의 및 범위
  • 주요 조사 결과
    • 영향 요인
    • 주요 투자 기회
  • Porter's Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
      • 세계의 암 이환율 증가
      • 노년 인구 증가
      • 면역관문억제제에 대한 지원적인 상환 정책
    • 억제요인
      • 면역관문억제제의 고가격
    • 기회
      • 파이프라인 의약품 증가
      • 신흥 시장에서의 성장 기회

제4장 면역관문억제제 시장 : 유형별

  • 개요
  • CTLA-4 억제제
  • PD-1 억제제
  • PD-L1 억제제

제5장 면역관문억제제 시장 : 용도별

  • 개요
  • 폐암
  • 방광암
  • 흑색종
  • 대장암
  • 호지킨 림프종
  • 기타

제6장 면역관문억제제 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 기타
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 기타
  • 라틴아메리카, 중동 및 아프리카
    • 브라질
    • 기타

제7장 경쟁 구도

  • 서문
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝(2022년)

제8장 기업 프로파일

  • Merck & Co., Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • BeiGene, Ltd.
  • Shanghai Junshi Biosciences Co., Ltd.
  • GlaxoSmithKline plc
  • Innovent Biologics, Inc.
AJY 24.02.13

According to a new report published by Allied Market Research, titled, "Immune Checkpoint Inhibitors Market," The immune checkpoint inhibitors market was valued at $40.1 billion in 2022, and is estimated to reach $189.4 billion by 2032, growing at a CAGR of 16.8% from 2023 to 2032.

Immune Checkpoint Inhibitors Market - IMG1

Cancer cells exploit these checkpoints to evade the immune system's detection and destruction. Immune checkpoint inhibitors work by targeting and blocking specific proteins, such as PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), which are involved in these checkpoints. By inhibiting these proteins, these drugs enable the immune system to more effectively identify and combat cancer cells.

The major factors driving the growth of immune checkpoint inhibitors market are advancements in R&D, increase in prevalence of cancer cases, increase in number of clinical trials, expanding research initiatives, strategic collaborations, and growing approvals for new indications. Cancer remains a leading cause of mortality globally, with continuous rise in diagnosed cases across various cancer types. For instance, National Cancer Institute, Division of Cancer Control & Population Sciences (DCCPS), stated that, 623,405 people are living with metastatic breast, prostate, lung, colorectal cancer, or metastatic melanoma in the U.S. As the burden of cancer grows, there is a pressing need for more effective treatment options, leading to the heightened demand for immune checkpoint inhibitors.

Further, increase in the number of clinical trials focusing on the immune checkpoint inhibitors is expected to fuel the market growth. There is a growing inclination among pharmaceutical companies, biotechnology firms, and academic institutions to allocate more resources toward clinical research. This investment aims to scrutinize the safety, effectiveness, and possible uses of immune checkpoint inhibitors across diverse cancer types. These trials, focused on investigating novel drug combinations, evaluating treatment reactions, and pinpointing predictive biomarkers, significantly contribute to broadening the comprehension of immune-driven treatments. For instance, in July 2023, Merck & Co., Inc., and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma. The results from these trials not only drive drug development but also inform treatment decisions, further boosting the growth of the immune checkpoint inhibitors market.

Furthermore, strategic collaborations among pharmaceutical companies, biotechnology firms, and academic institutions have emerged as a key factor propelling the growth of the immune checkpoint inhibitors market. Partnerships and alliances facilitate the consolidation of expertise, resources, and technologies, expediting the drug discovery and development process. For instance, in May 2020, Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic & other major diseases, and The University of Texas MD Anderson Cancer Center, announced a strategic collaboration agreement to co-develop TYVYT (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, for treating rare cancers in the U.S. In addition, collaborative efforts facilitate the exploration of diverse therapeutic applications, the conduct of larger clinical trials, and the accelerated translation of research findings into clinical applications. Such collaborations have led to the successful development and commercialization of several immune checkpoint inhibitors, widening their reach and applications in oncology.

The immune checkpoint inhibitors market is segmented on the basis of product type, application, and region. By product type, the market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. On the basis of application, the market is classified into lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).

Major key players that operate in the global immune checkpoint inhibitors market are Merck & Co., Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, BeiGene, Ltd., Shanghai Junshi Biosciences Co., Ltd., GlaxoSmithKline plc, and Innovent Biologics, Inc. The key players have adopted strategies such as acquisition, agreement, strategic alliance, collaboration, clinical trial, expansion, joint venture, new product development, and product approval to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the immune checkpoint inhibitors market analysis from 2022 to 2032 to identify the prevailing immune checkpoint inhibitors market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the immune checkpoint inhibitors market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global immune checkpoint inhibitors market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • CTLA-4 inhibitor
  • PD-1 inhibitor
  • PD-L1 inhibitor

By Application

  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Colorectal Cancer
  • Hodgkin lymphoma
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Rest of LAMEA

Key Market Players:

    • Merck & Co., Inc.
    • AstraZeneca plc
    • Merck KGaA
    • Bristol-Myers Squibb Company
    • BeiGene, Ltd.
    • Shanghai Junshi Biosciences Co., Ltd.
    • GlaxoSmithKline plc
    • Innovent Biologics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in incidences of cancer across the globe
      • 3.4.1.2. Rise in geriatric population
      • 3.4.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
    • 3.4.2. Restraints
      • 3.4.2.1. Higher cost of immune checkpoint inhibitors
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in number of pipeline drugs
      • 3.4.3.2. Growth opportunities in emerging markets

CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CTLA-4 inhibitor
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. PD-1 inhibitor
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. PD-L1 inhibitor
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Lung Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Bladder Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Melanoma
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Colorectal Cancer
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Hodgkin lymphoma
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Others
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country

CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Type
      • 6.2.4.1.2. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Type
      • 6.2.4.2.2. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Type
      • 6.2.4.3.2. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Type
      • 6.3.4.1.2. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Type
      • 6.3.4.2.2. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Type
      • 6.3.4.3.2. Market size and forecast, by Application
      • 6.3.4.4. Rest of Europe
      • 6.3.4.4.1. Market size and forecast, by Type
      • 6.3.4.4.2. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Type
      • 6.4.4.1.2. Market size and forecast, by Application
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Type
      • 6.4.4.2.2. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Market size and forecast, by Type
      • 6.4.4.3.2. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Market size and forecast, by Type
      • 6.4.4.4.2. Market size and forecast, by Application
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Type
      • 6.4.4.5.2. Market size and forecast, by Application
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Type
      • 6.4.4.6.2. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Type
      • 6.5.4.1.2. Market size and forecast, by Application
      • 6.5.4.2. Rest of LAMEA
      • 6.5.4.2.1. Market size and forecast, by Type
      • 6.5.4.2.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Merck & Co., Inc.
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. AstraZeneca plc
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. F. Hoffmann-La Roche Ltd.
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Merck KGaA
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Regeneron Pharmaceuticals, Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Bristol-Myers Squibb Company
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. BeiGene, Ltd.
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Shanghai Junshi Biosciences Co., Ltd.
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. GlaxoSmithKline plc
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. Innovent Biologics, Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제